Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17473814 | 0.78 | TLR7 (0.71) | TLR7 | |
| SCHEMBL2387953 | 0.75 | TLR7 (0.78) | TLR7 | |
| SCHEMBL17473818 | 0.72 | TLR7 (0.59) | TLR7 | |
| SCHEMBL12028703 | 0.72 | TLR7 (0.42) | TLR7MAPTTP53THRBTSHR | |
| SCHEMBL2392975 | 0.71 | PLA2G4B (0.48) | TLR7MAPTTP53THRBTSHR | |
| SCHEMBL6322342 | 0.67 | TSHR (0.61) | MAPTTP53THRBTSHRALDH1A1 | |
| SCHEMBL5090793 | 0.67 | TSHR (0.61) | MAPTTP53THRBTSHRALDH1A1 | |
| SCHEMBL2388565 | 0.67 | TLR7 (0.77) | TLR7 | |
| SCHEMBL2389826 | 0.66 | TLR7 (0.53) | TLR7MAPTMAPK1SMN1; SMN2LMNA | |
| SCHEMBL7937774 | 0.66 | MAPT (0.82) | MAPTTP53TSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1728793-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | IFNAR1, IL5, IFNG | TLR7 8/4885MAPT 4844/4885TP53 4535/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | TLR7 8/4885MAPT 4844/4885TP53 4535/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | TLR7 13/4885MAPT 4853/4885TP53 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.